These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 11978778

  • 1. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
    Naves R, Lennon AM, Barbieri G, Reyes L, Puga G, Salas L, Deffrennes V, Rosemblatt M, Fellous M, Charron D, Alcaïde-Loridan C, Bono MR.
    Int Immunol; 2002 May; 14(5):481-91. PubMed ID: 11978778
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y, McDonald J, Perloff E, Butticè G, Schreiber BM, Smith BD.
    Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
    [Abstract] [Full Text] [Related]

  • 4. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
    Holtz R, Choi JC, Petroff MG, Piskurich JF, Murphy SP.
    Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The RAG cell line defines a new complementation group of MHC class II deficiency.
    Lennon A, Ottone C, Peijnenburg A, Hamon-Benais C, Colland F, Gobin S, van den Elsen P, Fellous M, Bono R, Alcaïde-Loridan C.
    Immunogenetics; 1996 Sep; 43(6):352-9. PubMed ID: 8606055
    [Abstract] [Full Text] [Related]

  • 10. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression.
    Dong Y, Tang L, Letterio JJ, Benveniste EN.
    J Immunol; 2001 Jul 01; 167(1):311-9. PubMed ID: 11418665
    [Abstract] [Full Text] [Related]

  • 11. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
    Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G.
    Cell Growth Differ; 2001 Jun 01; 12(6):327-35. PubMed ID: 11432807
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases.
    Yau AC, Piehl F, Olsson T, Holmdahl R.
    Immunology; 2017 Apr 01; 150(4):408-417. PubMed ID: 27861821
    [Abstract] [Full Text] [Related]

  • 14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ.
    Invest Ophthalmol Vis Sci; 2004 Sep 01; 45(9):3185-95. PubMed ID: 15326139
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.
    Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA.
    Immunity; 1996 Feb 01; 4(2):167-78. PubMed ID: 8624807
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.